ID   M376
AC   CVCL_XK11
DR   cancercelllines; CVCL_XK11
DR   Wikidata; Q95984239
RX   PubMed=22194965;
RX   PubMed=27533468;
CC   Sequence variation: Gene deletion; HGNC; HGNC:9588; PTEN; Zygosity=Heterozygous (PubMed=22194965).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22194965; PubMed=27533468).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=22194965; PubMed=27533468).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 19-12-24; Version: 8
//
RX   PubMed=22194965; DOI=10.1371/journal.pone.0028973; PMCID=PMC3237573;
RA   Atefi M., von Euw E.M., Attar N., Ng C., Chu C., Guo D.-L., Nazarian R.,
RA   Chmielowski B., Glaspy J.A., Comin-Anduix B., Mischel P.S., Lo R.S.,
RA   Ribas A.;
RT   "Reversing melanoma cross-resistance to BRAF and MEK inhibitors by
RT   co-targeting the AKT/mTOR pathway.";
RL   PLoS ONE 6:e28973.1-e28973.12(2011).
//
RX   PubMed=27533468; DOI=10.1080/15384101.2016.1208862; PMCID=PMC5026796;
RA   Malka-Mahieu H., Girault I., Rubington M., Leriche M., Welsch C.,
RA   Kamsu-Kom N., Zhao Q., Desaubry L., Vagner S., Robert C.;
RT   "Synergistic effects of eIF4A and MEK inhibitors on proliferation of
RT   NRAS-mutant melanoma cell lines.";
RL   Cell Cycle 15:2405-2409(2016).
//